Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...
GlobalData on MSN12d
AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patientsDatopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall ...
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
12d
AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) datopotamab deruxtecan (Dato-DXd) did not significantly improve overall ...
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...
--(BUSINESS WIRE)--Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback